|The somatic genomic landscape of glioblastoma|
CW Brennan, RGW Verhaak, A McKenna, B Campos, H Noushmehr, ...
cell 155 (2), 462-477, 2013
|Integrated genomic characterization of endometrial carcinoma|
Nature 497 (7447), 67-73, 2013
|The molecular taxonomy of primary prostate cancer|
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
|The evolutionary history of lethal metastatic prostate cancer|
G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, J Tubio, ...
Nature 520 (7547), 353-357, 2015
|Evaluation of methods for modeling transcription factor sequence specificity|
MT Weirauch, A Cote, R Norel, M Annala, Y Zhao, TR Riley, ...
Nature biotechnology 31 (2), 126-134, 2013
|Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerctDNA and Resistance to AR-Targeted Therapy|
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
|Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer|
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
JAMA oncology 2 (12), 1598-1606, 2016
|Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer|
AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ...
JNCI: Journal of the National Cancer Institute 109 (12), 2017
|The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma|
BC Parker, MJ Annala, DE Cogdell, KJ Granberg, Y Sun, P Ji, X Li, ...
The Journal of clinical investigation 123 (2), 2013
|Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP InhibitorsCfDNA Finds PARPi …|
D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ...
Cancer discovery 7 (9), 999-1005, 2017
|Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 …|
DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ...
The Lancet Oncology 20 (12), 1730-1739, 2019
|A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding|
Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, ...
Nature genetics 46 (2), 126-135, 2014
|Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer|
M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ...
European urology 72 (1), 34-42, 2017
|Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer|
G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ...
European urology 75 (4), 667-675, 2019
|Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network|
KM Holmes, M Annala, CYX Chua, SM Dunlap, Y Liu, N Hugen, ...
Proceedings of the National Academy of Sciences 109 (9), 3475-3480, 2012
|Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression|
L Latonen, E Afyounian, A Jylhä, J Nättinen, U Aapola, M Annala, ...
Nature communications 9 (1), 1-13, 2018
|Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours|
BC Parker, M Engels, M Annala, W Zhang
The Journal of pathology 232 (1), 4-15, 2014
|Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerctDNA Alterations in Metastatic Bladder Cancer|
G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ...
Clinical Cancer Research 23 (21), 6487-6497, 2017
|Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate CancerPCAT5: An ERG-Regulated lncRNA|
A Ylipää, K Kivinummi, A Kohvakka, M Annala, L Latonen, M Scaravilli, ...
Cancer research 75 (19), 4026-4031, 2015
|Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyMolecular Analysis High-Risk …|
H Beltran, AW Wyatt, EC Chedgy, A Donoghue, M Annala, EW Warner, ...
Clinical Cancer Research 23 (22), 6802-6811, 2017